About this trial
To develop digital biomarkers associated with disease activity of inflammatory bowel disease
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Males or females aged > 18 years
Diagnosis of CD, UC or IBD-unspecified for at least 1 month
Treatment with conventional or advanced therapy for IBD at initiation of the study
The patient must have access to an email address
Disqualifiers
Planned extended (> 1 month) overseas travel during the study period of 12 months, if internet access would be impossible, inconvenient or unaffordable during this time
Previous colectomy
Inability to communicate well with investigators or unable to comply with the study requirements
Significant medical condition interfering with physiological measurements trough a wearable device (heart failure, pacemaker or defibrillator)
Trial population
This is an open label observational trial with partially blinded data collection (wearable and shopping data blinded for the patient and treating HCP). Patients in the study will not be randomized. Patients will be recruited via planned outpatient visits and day clinic admissions. Patients will be allocated to one of the three target patient groups at the investigator's discretion. 1. Patients with IBD in longstanding remission (\>2 years) (maximum of 20 patients) 2. Patients with IBD recent event (diagnosis or flare of IBD) (\<1year) (minimum 20 patients) 3. Additional patients with IBD in standard follow up. From the moment 60 patients are included, no additional patients can be recruited in group 1 or 3 prior to completion of group 2.
Trial design
Cohort
Prospective
Treatments tested in this trial
monitoring of wearable data, shopping data, biomarkers and patient reported outcomes
Device1. All participants will receive a wearable device type Corsano Health Cardio watch 287-2 which is provided by the sponsor via Inovigate. Participants will be encouraged to wear the device 24h per day and need to wear the wearable device at least 12 hours per day, preferential during daytime. 2. All participants will receive a loyalty card (Xtra card Colruyt group) which is provided by the sponsor via Inovigate for food data capturing. The patient is requested to execute all grocery shopping at one of the Colruyt Group stores. He/she will always need to offer the loyalty card to the cashier prior to payment. The purchase receipt will then be automatically sent to the central food data repository at the sponsor set up for this study. Non-food or non-food related data will neither be captured nor stored during the trial. 3. biomarkers in blood and feaces will be monitored according to standard of care 4. patient reported outcomes will be monitored according to standard of care
Treatment groups
Trial outcomes
Primary outcomes
Proportion of patients in which a flare can be detected based on passive monitoring data.
Secondary outcomes
Proportion of patients in which a biomarker flare can be detected based on passive monitoring data
Proportion of patients in which an objective disease flare (combination of flare and biomarker flare) can be detected based on passive monitoring
Proportion of patients in which a flare can be detected based on food purchase data
Proportion of patients in which a biomarker flare can be detected based on food purchase data
Other outcomes
- Interval between onset of a flare and detection based on passive monitoring data
exploratory outcome
- Subgroup analysis based on the food frequency questionnaire
Exploratory outcome
- Patient satisfaction based on patient experience questionnaire
Exploratory outcome
- Proportion of patients in which (different levels of) disability can be detected based on passive monitoring data
.exploratory outcome
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Imelda GI Clinical Research Center
Lead sponsor
Agentschap Innoveren & Ondernemen (VLAIO)
Collaborator
This trial is not recruiting at the moment. You can still explore other options: